Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

3077 results about "Pyrazole" patented technology

Pyrazole is an organic compound with the formula C₃H₃N₂H. It is a heterocycle characterized by a 5-membered ring of three carbon atoms and two adjacent nitrogen atoms. Pyrazole is a weak base, with pKb 11.5 (pKₐ of the conjugated acid 2.49 at 25 °C). Pyrazoles are also a class of compounds that have the ring C₃N₂ with adjacent nitrogen atoms. Notable drugs containing a pyrazole ring are celecoxib (Celebrex) and the anabolic steroid stanozolol.

Substituted pyrazolo piperidine carboxylic acids

The invention relates to substituted pyrazolo piperidine carboxylic acids, their salts and to processes for their preparation, and also to their use for preparing medicaments for the treatment and / or prophylaxis of diseases, in particular cardiovascular and cardiac diseases, preferably heart failure with reduced and preserved ejection fraction (HFrEF, HFmrEF and HFpEF), hypertension (HTN), peripheral arterial diseases (PAD, PAOD), cardio-renal and kidney diseases, preferably chronic and diabetic kidney disease (CKD and DKD), cardiopulmonary and lung diseases, preferable pulmonary hypertension (PH), and other diseases, preferably neurodegenerative diseases and different forms of dementias, fibrotic diseases, systemic sclerosis (SSc), sickle cell disease (SCD), wound healing disorders such as diabetic foot ulcer (DFU).
Owner:BAYER AG

Process of making 2-[(3R)-2-[4-amino-3-(2-fluoro-4-phenoxy- phenyl)pyrazolo[3,4-d]pyrimidin-l-YL]piperidine-l-carbonyl]-4- methyl-4[4-(oxetan-3-YL)piperazin-l-YL]-pent-2-enenitrile and solvate forms thereof

PCT designated stage expiredWO2025029842A2Organic active ingredientsAntipyreticPiperazidinePhenyl group
Disclosed herein are novel methods for preparing 2-[(3R)-2-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4[4-(oxetan-3-yl)piperazin-1-yl]-pent-2-enenitrile, including various solvate forms and intermediates thereof. Also disclosed herein are novel solvate forms and intermediates of 2-[(3R)-2-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4[4-(oxetan-3-yl)piperazin-1-yl]-pent-2-enenitrile.
Owner:PRINCIPIA BIOPHARMA INC

Nitrification inhibitor and preparation method thereof, and stable urea and preparation method thereof

The invention provides a nitrification inhibitor and a preparation method thereof as well as stable urea and a preparation method thereof, and relates to the technical field of fertilizers. The nitrification inhibitor provided by the invention is prepared from the following components in percentage by mass: 20 to 45 percent of 3, 4-dimethyl pyrazole phosphate (DMPP), 30 to 70 percent of amino acid and the balance of auxiliaries, the auxiliary agent is one or more of polysaccharide, polyvinylpyrrolidone, poloxamer and carbomer. According to the invention, the DMPP and the amino acid are compounded, the amino acid is used as a stabilizer of the DMPP, so that the stability of the DMPP can be remarkably improved, and meanwhile, the polymer additive is used as an adhesive, so that the stability of the DMPP can be further improved. The nitrification inhibitor provided by the invention has excellent stability; the stable urea can be obtained by adopting an endogenous adding mode and adding the stable urea into the urea with relatively low loss, and the stable urea has multiple effects of improving the urea utilization rate, improving the crop quality, improving the soil biological environment, improving the soil fertility and the like.
Owner:CHANGZHOU VOCATIONAL INST OF ENG

Methods for treating immune thrombocytopenia by administering (R)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile

Methods for treating immune thrombocytopenia comprising administering at least one compound chosen from (R)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile (PRN1008) and pharmaceutically acceptable salts thereof are disclosed. Pharmaceutical compositions comprising at least one compound chosen from PRN1008 and pharmaceutically acceptable salts thereof are also disclosed.
Owner:PRINCIPIA BIOPHARMA INC

Preparation method of pyrazolone amino-acid ester derivative

The invention discloses a preparation method of a pyrazolone amino-acid ester derivative. The pyrazolone amino-acid ester derivative is obtained through three-component cascade reaction by taking pyrazolone imine, a pentafluorophenylacetate derivative and alcohol as reactants and chiral isothiourea as a catalyst. According to the invention, challenges of competitive side reactions between a plurality of reaction substrates and intermediates and stereoselectivity control are overcome, the application range of the substrate combination of the existing system is broken through, and synthesis of a series of pyrazolone amino-acid ester derivatives is realized in a green and efficient manner. According to the method disclosed by the invention, substrate preassembly is not needed, transition metal catalysis is not needed, raw materials and the catalyst are cheap and easy to obtain, reaction conditions are mild, and the substrate application range is wide. In addition, the invention also provides a new way for introducing the medicine bioactive molecules into the synthesis of the pyrazolone amino-acid ester compound.
Owner:FUJIAN NORMAL UNIV

Methods for treating persistent or chronic immune thrombocytopenia in children, adolescents and adults by administering (r)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy- phenyl)pyrazolo[3,4-d]pyrimidin-l-YL]piperidine-l-carbonyl]-4- methyl-4-[4-(oxetan-3-YL)piperazin-l-YL]pent-2-enenitrile

Methods for treating children, adolescents and adults with persistent or chronic immune thrombocytopenia comprising administering at least one compound chosen from (R)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile (rilzabrutinib) and pharmaceutically acceptable salts thereof are disclosed.
Owner:PRINCIPIA BIOPHARMA INC

Synthesis method of 1-methyl-3-trifluoromethyl-4-chloromethyl-5-difluoromethoxy-1-H-pyrazole

The invention relates to the technical field of pesticide production, in particular to a synthesis method of 1-methyl-3-trifluoromethyl-4-chloromethyl-5-difluoromethoxy-1-H-pyrazole, which at least comprises the following steps: firstly, mixing trioxymethylene and 1-methyl-3-trifluoromethyl-5-difluoromethoxy-1-H-pyrazole to prepare a solution A; the solution A and chlorosulfonic acid are mixed and then subjected to a chloromethylation reaction, 1-methyl-3-trifluoromethyl-4-chloromethyl-5-difluoromethoxy-1-H-pyrazole is obtained through aftertreatment after sampling detection is qualified, and the method is high in product yield, high in purity, low in production cost, high in production efficiency, easy to operate, capable of meeting the green and environment-friendly requirements and suitable for industrial production. The industrial production is easy to realize.
Owner:SULI (NINGXIA) NEW MATERIAL TECH CO LTD

Pharmaceutical composition containing pyrazole ether compound and application thereof

The invention provides a pharmaceutical composition containing a pyrazole ether compound and application of the pharmaceutical composition, the pharmaceutical composition comprises an effective component A and an effective component B. The effective component A is a pyrazole ether compound with a structure shown in a formula I; and the effective component B is selected from any one or a combination of at least two of azole bactericides, mitochondrial electron transport chain compound III inhibitor bactericides, SDHI bactericides, multi-site contact type bactericides or other bactericides. In the invention, the effective component A and the effective component B have a synergistic effect, so that the pharmaceutical composition has higher biological activity and favorable or wider active spectrum, can reduce the application amount of compounds and compositions required for effectively controlling phytopathogens, and has longer lasting activity.
Owner:SHANGHAI XIAOMING DETECTION TECH SERVICE CO LTD

Method for detecting content of monosaccharide components in bacterial capsular polysaccharide or conjugate thereof

The invention discloses a method for detecting the content of monosaccharide components in bacterial capsular polysaccharide or a conjugate thereof, and belongs to the field of biological product detection. Taking pneumococcus as an example, different hydrolysis methods are adopted for different serotypes of capsular polysaccharides, connected glucosidic bonds are broken through hydrolysis, released monosaccharide components and 1-phenyl-3-methyl-5-pyrazolone are subjected to derivatization under the alkaline condition to generate derivatives with ultraviolet absorption, and then the capsular polysaccharides with different serotypes are obtained. And then detecting the composition and the content of each monosaccharide generated by polysaccharide hydrolysis through liquid chromatography. According to the method, each monosaccharide component can be quickly and effectively hydrolyzed, meanwhile, various polysaccharides with different structural characteristics can be separated and detected by adopting a derivatization method, whether the monosaccharide composition of each serotype polysaccharide accords with a theoretical structure or not can be qualitatively analyzed, and the content of each monosaccharide component can be quantitatively determined to calculate the content of the polysaccharides; and a better technical support is provided for quality control of the antigen component capsular polysaccharide of the bacterial vaccine.
Owner:FOSUN ADGENVAX BIOTECHONOLOGY CO LTD

Crystalline 19-nor C3,3-disubstituted C21-n-pyrazolyl steroid

This invention relates to a crystalline 19-nor C3,3-disubstituted C21-pyrazolyl steroid of Formula (I),and compositions thereof. Also disclosed herein are methods of making the same and methods of using the same.
Owner:SAGE THERAPEUTICS LLC

Defective metal organic framework antioxidant nano-enzyme as well as preparation method and application thereof

The invention discloses a defective metal organic framework antioxidant nano-enzyme as well as a preparation method and application thereof, and belongs to the technical field of nano-biology. The preparation method comprises the following steps: dissolving a copper source, a zirconium source and an organic ligand containing pyrazole and carboxyl in an organic solvent, then adding a competitive ligand, uniformly mixing, and carrying out solvothermal reaction at 80-120 DEG C to prepare the defective metal organic framework; after a defective metal organic framework aqueous solution and a kidney targeting molecular solution are uniformly mixed, the defective metal organic framework anti-oxidation nano-enzyme is obtained through coordination and electrostatic adsorption effects. The organic ligand containing pyrazole and carboxyl, the competitive ligand containing carboxylic acid and the organic solvent are matched to adjust the particle size and the defect, the metal organic framework with the small particle size and the defect is prepared, the antioxidant activity is improved, kidney targeting molecules are loaded to obtain the defect metal organic framework antioxidant nano-enzyme, and the kidney targeting effect is achieved.
Owner:FOURTH MILITARY MEDICAL UNIVERSITY

Pretreatment method for liquid chromatography-tandem mass spectrometry of pesticide and veterinary drug residues in serum

The invention belongs to the technical field of liquid chromatography-mass spectrometry detection pretreatment, and particularly relates to a pretreatment method for liquid chromatography-tandem mass spectrometry analysis of pesticide and veterinary drug residues in serum, which comprises the following steps: (S1) carrying out heating reaction on Sc (III) salt, Cu (II) salt and 1H-pyrazole-4-formic acid (H2PyC) in a polar aprotic solvent, and cooling to obtain a green crystal, namely MOF-919; the chemical formula of the MOF-919 is [Sc < 3 > (mu3-O) (OH) < 3 >] [Cu3 (mu3-O) (mu-PyC) < 3 > (H2O) < 6 >] < 2 >; (S2) mixing the serum sample with an acetonitrile solution containing formic acid, carrying out ultrasonic treatment, vortex oscillation and centrifugation, taking supernate, and diluting the supernate with an aqueous solution containing formic acid to obtain a to-be-purified solution; and (S3) adding MOF-919 into the to-be-purified liquid, mixing, performing ultrasonic treatment, performing vortex oscillation, centrifuging, and taking supernate, thereby completing the pretreatment of the to-be-purified liquid. According to the method, the MOF-919 is used for adsorbing chemical pollutant residues in serum, especially phospholipids, so that the purpose of removing the chemical pollutant residues in blood is achieved. The method is simple and convenient to operate, small in organic solvent consumption and good in purification effect, and can be widely applied to residue analysis of chemical pollutants in serum.
Owner:BEIJING CENT FOR DISEASE PREVENTION & CONTROL

4-pyrazolo[1,5-a]pyridin-2-yl-4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine derivatives as mutant PAH protein stabilizers for the treatment of phenylketonuria

PCT designated stage expiredWO2025049662A1Organic active ingredientsNervous disorderMutated proteinPhenylalanine hydroxylase cofactor
The disclosure is directed to 4-pyrazolo[1,5-a]pyridin-2-yl-4, 5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine derivatives of formula (I) and pharmaceutically acceptable salts thereof, that stabilize phenylalanine hydroxylase (PAH) mutations, pharmaceutical compositions comprising those compounds, and methods of using those compounds in methods for stabilizing a mutant PAH protein or reducing blood phenylalanine concentration in a subject suffering from phenylketonuria. In some embodiments, the mutant PAH protein contains at least one R408W, R261Q, R243Q, Y414C, L48S, A403V, I65T, R241C, L348V, R408Q, or V388M mutation. In other embodiments, the mutant PAH protein contains at least one R408W, Y414C, I65T, F39L, R408Q, L348V, R261Q, A300S, or L48S mutation.
Owner:AGIOS PHARMACEUTICALS INC

Pyrazole fused ring compound as well as preparation method and application thereof

The invention relates to a pyrazole fused ring compound as well as a preparation method and application thereof. Specifically, the invention relates to a compound shown in a general formula (I), a preparation method of the compound, a pharmaceutical composition containing the compound and application of the compound serving as an FGFR inhibitor in tumor treatment. Wherein each group in the general formula (I) is defined in the specification. # imgabs0 #
Owner:JIANGSU YAHONG MEDITECH CO LTD +1

Anthraquinone-based MOF photocatalytic material as well as preparation method and application thereof

The invention discloses an anthraquinone-based MOF photocatalytic material as well as a preparation method and application thereof. The anthraquinone-based MOF photocatalytic material is prepared by carrying out solvothermal reaction on a ligand DPAq and a nickel source in a mixed solvent, wherein the ligand DPAq is 2, 6-bis (pyrazol-4-yl)-9, 10 anthraquinone, and the mixed solvent is a composition of N, N-dimethylformamide and water. The anthraquinone-based MOF photocatalytic material shows an appropriate band gap and good ROS generation efficiency and shows excellent catalytic activity and selectivity when applied to benzylamine coupling reaction, the reaction selectivity reaches 100%, the product yield can reach 97%, and the catalytic reaction efficiency is high; the product can be recycled, and the yield of the product can still reach 92% after the product is recycled for 5 times.
Owner:GUANGXI UNIV FOR NATITIES

Selective etching solution for titanium and / or copper metal layer of circuit board and preparation method of selective etching solution

PendingCN120041833AEtchingO-Phosphoric Acid
The invention discloses a selective etching solution for a titanium and / or copper metal layer of a circuit board and a preparation method of the selective etching solution, and the selective etching solution comprises the following components: 10-20% of persulfate, 4-8% of o-nitrobenzenesulfonate, 0.5-1% of phosphoric acid, 0.2-0.8% of 3-(aminomethyl) pyrazole, 0.3-1.5% of ammonium fluoride, 2-5% of cyclohexanediamine tetraacetic acid, 0.1-0.5% of cyclodextrine and the balance of water. The etching solution can selectively etch a titanium and / or copper metal layer, through selection and cooperation of etching solution components, etching is uniform and stable, taper angle and lateral etching control is good, metal wires are smooth, no metal residues exist, and a good etching solution is provided for the circuit board etching process.
Owner:XINFENG RONGWEIYE TECH CO LTD

4 (1H-pyrazol-3-yl) piperidinyl derivative, preparation method thereof and application of 4 (1H-pyrazol-3-yl) piperidinyl derivative in preparation of MNK inhibitor

The invention provides a 4 (1H-pyrazol-3-yl) piperidinyl derivative, the structural formula of the 4 (1H-pyrazol-3-yl) piperidinyl derivative is shown as a formula I, # imgabs0 #, R1 is an aromatic ring or a substituted aromatic ring, the substituted aromatic ring is a substituent group on the aromatic ring, and R2 is a hydrogen atom or a hydrogen atom or a substituent group on the substituted aromatic ring, so that the structural formula of the 4 (1H-pyrazol-3-yl) piperidinyl derivative is shown as a formula I; the substituent groups are selected from C1-C6 alkyl groups, C1-C6 halogenated alkyl groups, C1-C6 alkylamino groups, C1-C6 alkoxy groups, five-membered to six-membered heterocyclic groups, halogen, hydroxyl groups, cyano groups, nitryl groups, amino groups and carbonyl substituted five-membered to six-membered heterocyclic groups containing 1-2 nitrogen atoms; and R2 is H or a C1-C6 alkyl group. The 4 (1H-pyrazol-3-yl) piperidinyl derivative has MNK1 and / or MNK2 inhibitory activity, and has anti-cancer and anti-inflammatory activity; the invention also provides a preparation method of the 4 (1H-pyrazol-3-yl) piperidinyl derivative, an application of the 4 (1H-pyrazol-3-yl) piperidinyl derivative in preparation of MNK1 and / or MNK2 inhibitors, and an application of the 4 (1H-pyrazol-3-yl) piperidinyl derivative in preparation of anti-inflammatory and anti-cancer drugs.
Owner:YANTAI NEW DRUG DEV SHANDONG PROVINCIAL LAB

Method for preparing 1-(4-chlorphenyl)-3-pyrazole alcohol through air oxidation

A method for preparing 1-(4-chlorphenyl)-3-pyrazole alcohol through air oxidation is characterized in that a eutectic solvent is adopted as a solvent and a catalyst, air oxidation reaction of 1-(4-chlorphenyl) pyrazolidine-3-ketone is dissolved and catalyzed to prepare the 1-(4-chlorphenyl)-3-pyrazole alcohol, the mass ratio of the 1-(4-chlorphenyl) pyrazolidine-3-ketone to the eutectic solvent is (1: 20)-(1: 10), and the mass ratio of the 1-(4-chlorphenyl) pyrazolidine-3-ketone to the eutectic solvent is (1: 20)-(1: 10). The method comprises the following steps of: reacting 1-(4-chlorphenyl)-3-pyrazole alcohol for 3-6 hours at the air flow velocity of 10-40L / min at the reaction temperature of 40-70 DEG C, after the reaction is finished, extracting the product 1-(4-chlorphenyl)-3-pyrazole alcohol for three times by using an extracting agent with the same volume as a reaction mixture, combining extracting solutions, and recovering the extracting agent through reduced pressure distillation to obtain the product 1-(4-chlorphenyl)-3-pyrazole alcohol, the yield is 98.2-99.4%, the purity is 98.7-99.5%, the raffinate is a eutectic solvent, and the method is suitable for industrial production. The direct recycling can be realized. The method has the characteristics of mild reaction conditions, simplicity and convenience in operation and high product yield; the eutectic solvent has dual functions of a solvent and a catalyst, can dissolve reaction raw materials and can provide a catalytic active center for the reaction, and the reaction efficiency is improved through the synergistic effect of the solvent and the catalyst; the eutectic solvent is easy to separate from the product, and the active center is not lost and can be repeatedly used.
Owner:QINGDAO UNIV OF SCI & TECH

Pyraclostrobin preparation device

The invention discloses a pyraclostrobin preparation device which comprises a reaction kettle and further comprises a temperature control cooling box, the temperature control cooling box is provided with a containing space, a partition part is arranged in the temperature control cooling box, the partition part divides the containing space into a cooling channel and a temperature control channel, and the temperature control channel is communicated with the cooling channel. The temperature control cooling box and the separation part are both made of heat conduction materials, a hydrothermal solution is introduced into the temperature control channel, and the temperature of the hydrothermal solution is higher than the crystallization temperature of pyraclostrobin. According to the pyraclostrobin preparation device provided by the invention, the reaction kettle and the temperature control cooling box are combined for use, so that a pyraclostrobin solution can circularly move between the reaction kettle and the temperature control cooling box, and precipitates and irregular crystals are fed into the reaction kettle for re-processing; the production speed of the pyraclostrobin crystals is increased, and meanwhile continuous production can be achieved.
Owner:JIANGSU SANSHAN PESTICIDE CO LTD

Pyrazolopyridine compound as RET inhibitor and application thereof

Disclosed is a series of pyrazolopyridine compounds, and application thereof in the preparation of RET kinase inhibitors for treatment. Specifically disclosed is the compound represented by formula (I), or a pharmaceutically acceptable salt thereof.
Owner:GUANGZHOU BAIYUNSHAN PHARMA HLDG CO LTD BAIYUNSHAN PHARMA GENERAL FACTORY

Preparation method of GLP1 RA and intermediate thereof

The invention relates to a preparation method of 3-[(1S, 2S)-1-[5-[(4S)-2, 2-dimethyl oxacyclohexane-4-yl]-2-[(4S)-2-(4-fluoro-3, 5-dimethyl phenyl)-3-[3-(4-fluoro-1-methylindazol-5-yl)-2-oxoimidazol-1-yl]-4-methyl-6, 7-dihydro-4H-pyrazolo [4, 3-c] pyridine-5-carbonyl] indol-1-yl]-2-methylcyclopropyl]-4H-1, 2, 3-triazolo [4, 3-c] pyridine-5-carbonyl] indol-1-yl]-2-methylcyclopropyl]-1, 2, 4-triazolo [4, 3-c] pyridine-5- The invention relates to synthesis of 1, 2, 4-oxadiazole-5-one or a salt thereof, and related synthesis intermediate compounds.
Owner:ELI LILLY & CO +1

Dry Film Resist, Photosensitive Dry Film, and Copper Clad Laminate

A dry film resist, a photosensitive dry film, and a copper clad laminate. The dry film resist includes an alkali-soluble resin (A), a photopolymerization monomer (B), a photoinitiator (C), and a sensitizer (D); and the sensitizer (D) includes a compound containing a pyrazoline structure.
Owner:HANGZHOU FIRST ELECTRONIC MATERIAL CO LTD

Rilzabrutinib for use in the treatment of ITCH associated with atopic dermatitis and / or prurigo nodularis

Methods for treating itch in human patients with atopic dermatitis (AD) and / or prurigo nodularis (PN) comprising administering a therapeutically effective amount of at least one compound chosen from (R)-2-[3-[4-amino-3-(2-fluoro-4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3- yl)piperazin-1-yl]pent-2-enenitrile (rilzabrutinib) and pharmaceutically acceptable salts thereof are disclosed.
Owner:PRINCIPIA BIOPHARMA INC

Pyrazolopyridine derivative having GLP-1 receptor agonist effect

The present invention provides a compound having the basic structure shown by Formula (I) in which the indole ring and the pyrazolopyridine structure is bound through a substituent, a salt thereof or a solvate of either the compound or a salt of the compound, as well as a preventative agent or a therapeutic agent for non-insulin-dependent diabetes mellitus (Type 2 diabetes) or obesity containing such compound, salt or solvate as an active ingredient.
Owner:CHUGAI PHARMA CO LTD

Pyrazole amide compound and use thereof

The present invention relates to the technical field of pesticides, and in particular to a pyrazole amide compound and a use thereof. The compound is as shown in general formula I, wherein Q represents O or S, W represents CH or N, X represents hydrogen, halogen, alkyl, etc., Y represents halogen or alkyl, Z represents alkyl, alkenyl, alkynyl, cycloalkyl, etc., and M represents hydrogen or alkyl. The compound has good prevention and treatment activity on pests such as green peach aphids, peanut aphids, and bird cherry-oat aphids.
Owner:QINGDAO KINGAGROOT CHEM COMPOUNDS CO LTD

High-temperature lithium ion battery electrolyte and lithium ion battery containing same

According to the high-temperature lithium ion battery electrolyte and the lithium ion battery containing the high-temperature lithium ion battery electrolyte, tris (trimethylsilane) phosphate, 2-(3-(trifluoromethyl)-1H-pyrazol-1-yl) acetonitrile and 1, 2, 3-trifluorobenzene are selected as additives in the electrolyte, and the three components can synergistically improve the high-temperature stability of the electrolyte, so that the high-temperature stability of the electrolyte is improved; and gas generated by thermal decomposition and side reaction is reduced, so that the risk that the internal pressure of the battery is abnormally increased or the battery swells due to the gas generated by the electrolyte in the high-temperature long-term storage process is reduced. Meanwhile, the influence of impurities in the electrolyte can be reduced, an electrochemical window is improved, the stability of the electrolyte can be kept at high temperature, and the service life of the battery can be prolonged.
Owner:SHENZHEN EPT BATTERY CO LTD

Bacillus subtilis for plant biological control and application thereof

The invention discloses bacillus subtilis LXN-1, and the bacillus subtilis LXN-1 is preserved in the China General Microbiological Culture Collection Center (CGMCC), and the preservation number is CGMCC.NO 31697. The bacillus subtilis LXN-1 is a bacillus subtilis LXN-1 strain. The bacillus subtilis LXN-1 has an inhibition effect on various plant pathogenic bacteria, the inhibition rate on tomato botrytis cinerea can reach 61.5%, the inhibition rate on tobacco brown spot caused by alternaria longibrachiata can reach 72%, the bacillus subtilis LXN-1 also has a virus resistance effect, the inhibition rate on tobacco TMV viral plaque can reach 95%, and the bacillus subtilis LXN-1 has a good application prospect. In addition, the bacillus subtilis LXN-1 also has the potential of being compounded with pesticide bactericides with iprodione, trifloxystrobin, difenoconazole, pyraclostrobin, copper oxychloride and copper hydroxide as main components for use, and has market popularization and application values, and absorption of the plants to nutrient elements can be enhanced, and the growth of the plants can be promoted, and the bacillus subtilis LXN-1 also has the potential of being compounded with the pesticide bactericides with the iprodione, the trifloxystrobin, the difenoconazole, the pyraclostrobin, the copper oxychloride and the copper hydroxide as main components.
Owner:SICHUAN AGRI UNIV +1

Methods for Treating Immune Thrombocytopenia By Administering (R)-2-[3-[4-Amino-3-(2-Fluoro-4-Phenoxy-Phenyl)Pyrazolo[3,4-D]Pyrimidin-1-YL]Piperidine-1-Carbonyl]-4-Methyl-4-[4-(Oxetan-3-YL)Piperazin-1-YL]Pent-2-Enentrile

Methods for treating immune thrombocytopenia comprising administering at least one compound chosen from (R)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile (rilzabrutinib) and pharmaceutically acceptable salts thereof are disclosed.
Owner:PRINCIPIA BIOPHARMA INC